Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

Serum Institute of India and University of Oxford strike landmark licensing agreement for Meningitis-B vaccine

Serum Institute of India Pvt. Ltd (SIIPL), in collaboration with the University of Oxford, is developing a novel solution for Men-B disease, advancing global accessibility to life-saving vaccines.

Prof Christoph Tang and Dr. Hayley S. Lavender in the lab where the Men B vaccine has been developed at the Dunn School of Pathology, University of Oxford

In a significant stride towards addressing the challenge of Men-B disease, Serum Institute of India Pvt. Ltd (SIIPL) and the University of Oxford have formalised a Licence of Technology Agreement negotiated by Oxford University Innovation.

This partnership will deliver lifesaving protection against Men-B through the production of a chimeric protein-based vaccine.

The agreement underscores the shared institutional commitment to combat disease caused by Neisseria meningitidis and represents a proactive response to overcome the limitations of currently available Men-B vaccines in terms of efficacy, safety, and coverage.

Read more on the Sir William Dunn School of Pathology website

The full story is also on the Oxford University Innovation website

Similar stories

The Nuffield Department of Women's & Reproductive Health's Clinical Research Group recruits its 2,000th participant to the Generation Study

Oxford’s Clinical Research Group (CRG) has reached an important milestone after recruiting its 2,000th participant to the nationwide Generation Study.

Dementias Platform UK (DPUK) blood biomarker project takes next step towards NHS dementia diagnosis

A project involving researchers from the Universities of Oxford and Cambridge, Imperial College London and Dementias Platform UK (DPUK) has been selected for a major UK initiative aimed at improving dementia diagnosis and helping more people access the support and treatment they need sooner.

Robotic hip and knee surgery fails to cut overall risk of repeat surgery

Two major studies from the University of Oxford, Queen Mary University of London and the University of Bristol, have found that robotic-assisted hip and knee replacement does not reduce the overall early risk of repeat surgery compared with conventional surgery.

Oxford medical student takes AI safety message to the Palace of Versailles

Oxford medical student Julian Shellard has presented at an international workshop on the future of Artificial Intelligence (AI) at the Palace of Versailles in Paris, highlighting the important role medical students can play in global conversations on shaping the future of science and medicine.

Everyday DNA damage reveals a hidden weakness in some cancers

Researchers in the Chapman Group at the MRC Weatherall Institute of Molecular Medicine, have discovered why cancer cells lacking a protein called ATM are particularly vulnerable to a class of cancer drugs known as PARP inhibitors, solving a scientific puzzle that has challenged researchers for nearly 20 years.

Dunn School publishes new children’s book to mark centenary

The collaboration with Oxford University Press brings the story of the development of Penicillin to a new audience